APO-PERINDOPRIL 2 MG
PERINDOPRIL ERBUMINE : 2 MG · DIN 02289261 · APOTEX INC
Health Canada status: MARKETED
What is APO-PERINDOPRIL?
APO-PERINDOPRIL 2 MG contains PERINDOPRIL ERBUMINE : 2 MG. It is listed in the Health Canada Drug Product Database under DIN 02289261, held by APOTEX INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 18-Dec-2020. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is APO-PERINDOPRIL used for?
Treatment of mild to moderate essential hypertension; mild to moderate congestive heart failure; reduction of cardiovascular risk in patients with stable coronary artery disease.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02289261 |
|---|---|
| Brand name | APO-PERINDOPRIL |
| Generic / active ingredient | PERINDOPRIL ERBUMINE : 2 MG |
| Manufacturer | APOTEX INC |
| Strength | 2 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | C09AA04 PERINDOPRIL |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 18-Dec-2020 |
How is it administered?
Hypertension: 4-8 mg daily. CHF: Init 2 mg daily, usual 4 mg daily. Stable CAD: Init 4 mg daily for 2 weeks, then 8 mg daily. Take once daily in the morning before a meal.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly stated in the provided text (refer to section 11).
How is it supplied?
Unit dose blister packages of 30 and 100 tablets; bottles of 100 and 500 tablets.
Contraindications
Hypersensitivity to drug/ACE inhibitors; history of angioedema; pregnancy/nursing; combination with sacubitril/valsartan or aliskiren (in diabetic/renal patients); bilateral renal artery stenosis.
Warnings and precautions
Serious Warning: Fetal injury/death in pregnancy. Risk of life-threatening angioedema (head/neck/intestinal), hypotension, and neutropenia/agranulocytosis. Caution in aortic stenosis.
Is PERINDOPRIL in shortage in Canada?
A Canadian shortage report is on file for this molecule: Anticipated — reported by SANIS HEALTH INC (Tier 3 Drug Shortages About & Resources), last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code C09AA04 PERINDOPRIL. 54 of 81 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AG-PERINDOPRIL ERBUMINE | 2 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02529491 |
| AG-PERINDOPRIL ERBUMINE | 4 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02529505 |
| AG-PERINDOPRIL ERBUMINE | 8 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02529513 |
| APO-PERINDOPRIL | 4 MG | TABLET | APOTEX INC | MARKETED | DIN 02289288 |
| APO-PERINDOPRIL | 8 MG | TABLET | APOTEX INC | MARKETED | DIN 02289296 |
| AURO-PERINDOPRIL | 2 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02459817 |
| AURO-PERINDOPRIL | 4 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02459825 |
| AURO-PERINDOPRIL | 8 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02459833 |
| BIO-PERINDOPRIL | 2 MG | TABLET | BIOMED PHARMA | MARKETED | DIN 02501309 |
| BIO-PERINDOPRIL | 4 MG | TABLET | BIOMED PHARMA | MARKETED | DIN 02501317 |
Who else supplies PERINDOPRIL worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. PERINDOPRIL appears in 603 registered pack listings across 13 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.